Chelsea Counsel Co. Boosts Stake in Solventum Corporation $SOLV

Key Points

• Chelsea Counsel Co. significantly increased its stake in Solventum Corporation by 720.7% during the 2nd quarter, owning 10,595 shares worth $804,000.
• Solventum Corporation reported earnings of $1.69 per share for the last quarter, exceeding analysts' expectations, with revenue reaching $2.16 billion.
• Equities analysts have set target prices for Solventum ranging from $77.00 to $94.00, with a consensus average target price of $84.60.

Chelsea Counsel Co. lifted its holdings in Solventum Corporation (NYSE:SOLV - Free Report) by 720.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,595 shares of the company's stock after buying an additional 9,304 shares during the period. Chelsea Counsel Co.'s holdings in Solventum were worth $804,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of SOLV. Rossby Financial LCC purchased a new position in shares of Solventum in the first quarter worth about $25,000. Strengthening Families & Communities LLC lifted its stake in shares of Solventum by 376.8% in the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock worth $25,000 after buying an additional 260 shares in the last quarter. Hara Capital LLC purchased a new position in shares of Solventum in the first quarter worth about $38,000. Smartleaf Asset Management LLC lifted its stake in shares of Solventum by 193.4% in the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company's stock worth $40,000 after buying an additional 352 shares in the last quarter. Finally, Costello Asset Management INC purchased a new position in Solventum during the first quarter worth about $42,000.

Solventum Trading Up 1.1%

Shares of SOLV stock opened at $72.98 on Wednesday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The stock has a market capitalization of $12.65 billion, a P/E ratio of 33.79, a price-to-earnings-growth ratio of 2.94 and a beta of 0.53. The company has a 50 day moving average price of $72.84 and a 200 day moving average price of $72.22. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. The firm had revenue of $2.16 billion during the quarter, compared to analysts' expectations of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities research analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Argus raised shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 target price on the stock in a research note on Tuesday, July 1st. UBS Group set a $77.00 target price on shares of Solventum in a research note on Wednesday. Piper Sandler reaffirmed an "overweight" rating and set a $94.00 target price (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. Jefferies Financial Group assumed coverage on shares of Solventum in a research note on Thursday, September 11th. They set a "hold" rating and a $80.00 target price on the stock. Finally, KeyCorp assumed coverage on shares of Solventum in a research note on Friday, June 6th. They set a "sector weight" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $84.60.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.